---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000006"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:22:50.773649+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere reports Q4 2022 net loss $65.8M; FDA granted accelerated approval for FILSPARI in IgAN

## Summary
- Net product sales $52.3M in Q4 2022 vs $54.6M in Q4 2021; full year $200.5M vs $210.8M.
- Net loss $65.8M ($1.03 per share) in Q4 2022 vs $51.6M ($0.84) in Q4 2021; full year loss $278.5M.
- Cash and marketable securities $450.2M as of Dec 31, 2022.
- FDA granted accelerated approval of FILSPARI (sparsentan) for IgAN on Feb 17, 2023; commercial launch expected week of Feb 27.
- Topline data from DUPLEX Study (FSGS) expected Q2 2023; EMA decision on sparsentan for IgAN expected H2 2023.

## SEC filing metadata
- accession: 0001438533-23-000006
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/0001438533-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/tvtx-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000006
- JSON: https://secwatch.observer/filing/0001438533-23-000006.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000006.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $55.9 million, net income ($65.8 million, or $1.03 per basic share).
  - Period: fourth quarter and full year ended December 31, 2022
  - Revenue: $55.9 million
  - Net income: ($65.8 million, or $1.03 per basic share)
  - Result: reported results
  source text: confirmatory endpoints in the ongoing Phase 3 PROTECT Study of sparsentan in IgAN expected in the fourth quarter of 2023 • Total revenue for the fourth quarter of 2022 was $55.9 million, consisting of $52.3 million in net product sales and $3.5 million in licensing and collaboration revenue • Total revenue for the full year 2022 was $212.0 million, consisting of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/0001438533-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.